retatrutide approval status eli lilly Phase 3 obesity trial results 2026 Seeking Differentiation Through a Triple

Microsurgery 41 (1), 3443

[DOI] [PMC free article] [PubMed] [Google Scholar] 17.Dilley A., Adhikari S., Silwal P., Lusk J., McFadden B

mL = mg (mg/mL), then Units = mL 100 (for U-100 syringes)

Zepbound, KwikPen, and LillyDirect are registered trademarks, and Foundayo is a trademark of Eli Lilly and Company

Tirzepatide is a dual GIP/GLP-1 receptor agonist while semaglutide acts only on GLP-1 receptors

Safety Monitoring To ensure safe escalation, clinical protocols monitored: Liver enzymes (ALT, AST) Kidney function Cardiovascular markers (blood pressure, lipids) Blood glucose in diabetic and non-diabetic participants So far, no significant cardiovascular safety issues have been reported, though long-term Phase 3 data will be critical before final conclusions can be made